NUZ — Neurizon Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- AU$56.62m
- AU$46.50m
Annual balance sheet for Neurizon Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 2.88 | 3.02 | 2.42 | 2.71 | 9.71 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.298 | 0.242 | 0.185 | 0.148 | 0.018 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.07 | 4.36 | 3.73 | 3.02 | 11.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.57 | 3.45 | 3.24 | 0.002 | 0 |
| Net Intangible Assets | |||||
| Total Assets | 10.7 | 11 | 10.1 | 6.13 | 11.1 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.06 | 0.911 | 1.17 | 1.35 | 0.896 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.22 | 2.07 | 2.23 | 2.24 | 0.897 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 8.53 | 8.88 | 7.84 | 3.89 | 10.2 |
| Total Liabilities & Shareholders' Equity | 10.7 | 11 | 10.1 | 6.13 | 11.1 |
| Total Common Shares Outstanding |